HomeCompareBLMHF vs ABBV

BLMHF vs ABBV: Dividend Comparison 2026

BLMHF yields 1826.48% · ABBV yields 3.06%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 BLMHF wins by $4280063890.14M in total portfolio value
10 years
BLMHF
BLMHF
● Live price
1826.48%
Share price
$0.11
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$4280063890.24M
Annual income
$3,863,914,374,048,000.00
Full BLMHF calculator →
ABBV
AbbVie Inc.
● Live price
3.06%
Share price
$217.44
Annual div
$6.65
5Y div CAGR
40.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$102.3K
Annual income
$24,771.77
Full ABBV calculator →

Portfolio growth — BLMHF vs ABBV

📍 BLMHF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodBLMHFABBV
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, BLMHF + ABBV cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
BLMHF pays
ABBV pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

BLMHF
Annual income on $10K today (after 15% tax)
$155,251.14/yr
After 10yr DRIP, annual income (after tax)
$3,284,327,217,940,800.00/yr
ABBV
Annual income on $10K today (after 15% tax)
$259.96/yr
After 10yr DRIP, annual income (after tax)
$21,056.00/yr
At 15% tax rate, BLMHF beats the other by $3,284,327,217,919,744.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of BLMHF + ABBV for your $10,000?

BLMHF: 50%ABBV: 50%
100% ABBV50/50100% BLMHF
Portfolio after 10yr
$2140031945.17M
Annual income
$1,931,957,187,036,386.00/yr
Blended yield
90.28%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ABBV right now

BLMHF
No analyst data
ABBV
Analyst Ratings
27
Buy
12
Hold
1
Sell
Consensus: Buy
Price Target
$256.15
+17.8% upside vs current
Range: $223.00 — $299.00
Altman Z
2.0
Piotroski
8/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

BLMHF buys
0
ABBV buys
0
No recent congressional trades found for BLMHF or ABBV in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricBLMHFABBV
Forward yield1826.48%3.06%
Annual dividend / share$2.00$6.65
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%40.6%
Portfolio after 10y$4280063890.24M$102.3K
Annual income after 10y$3,863,914,374,048,000.00$24,771.77
Total dividends collected$4250310142.07M$61.0K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: BLMHF vs ABBV ($10,000, DRIP)

YearBLMHF PortfolioBLMHF Income/yrABBV PortfolioABBV Income/yrGap
1← crossover$193,348$182,648.40$11,550$430.00+$181.8KBLMHF
2$3,507,329$3,300,446.41$13,472$627.96+$3.49MBLMHF
3$59,706,032$55,953,190.07$15,906$926.08+$59.69MBLMHF
4$954,075,544$890,190,089.76$19,071$1,382.55+$954.06MBLMHF
5$14,315,101,284$13,294,240,451.17$23,302$2,095.81+$14315.08MBLMHF
6$201,736,690,302$186,419,531,929.04$29,150$3,237.93+$201736.66MBLMHF
7$2,671,121,726,049$2,455,263,467,425.44$37,536$5,121.41+$2671121.69MBLMHF
8$33,240,572,674,989$30,382,472,428,116.90$50,079$8,338.38+$33240572.62MBLMHF
9$388,924,781,489,173$353,357,368,726,934.75$69,753$14,065.80+$388924781.42MBLMHF
10$4,280,063,890,241,416$3,863,914,374,048,000.00$102,337$24,771.77+$4280063890.14MBLMHF

BLMHF vs ABBV: Complete Analysis 2026

BLMHFStock

Maitri Health Technologies Corp. operates as a healthcare supply platform in Canada and internationally. The company offers personal protective equipment, and testing and technology solutions. Its products include face masks, face shields, anti-viral cleaning solutions, sanitizers, disinfectants, and PCR test kits. The company is based in Vancouver, Canada.

Full BLMHF Calculator →

ABBVHealthcare

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Full ABBV Calculator →
📬

Get this BLMHF vs ABBV comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

BLMHF vs SCHDBLMHF vs JEPIBLMHF vs OBLMHF vs KOBLMHF vs MAINBLMHF vs JNJBLMHF vs MRKBLMHF vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.